Business Wire (Thu, 5:05PM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
214 people get TARO articles and Market Currents by email alert.
Get email alerts on TARO »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Business Wire (May 16, 2013)
-
Business Wire (Apr 12, 2013)
-
Business Wire (Feb 8, 2013)
-
Business Wire (Feb 4, 2013)
-
Business Wire (Jan 25, 2013)
-
Business Wire (Nov 14, 2012)
-
Business Wire (Nov 8, 2012)
-
Business Wire (Nov 1, 2012)
-
Business Wire (Oct 23, 2012)
-
4 Low-Debt Healthcare Stocks Raking In ProfitsZetaKap • Fri, Sep 14, 2012
-
Business Wire (Aug 12, 2012)
-
Business Wire (Aug 6, 2012)
-
Business Wire (Jul 30, 2012)
To learn more about Seeking Alpha Pro, click here.
-
Templeton Wins Another One Against TaroAaron Katsman • Thu, Sep 20, 2007
-
Bid To Block Sale of Taro Pharmaceuticals Gains MomentumAaron Katsman • Fri, Jul 13, 2007
-
Taro Pharmaceutical: One for SpeculatorsShlomo Greenberg • Wed, May 9, 2007
-
Taro Pharmaceutical: A Bargain May Be BeckoningShlomo Greenberg • Thu, Apr 26, 2007
-
Taro Pharmaceutical: A Changing of the Guard?Shlomo Greenberg • Thu, Dec 14, 2006
-
Don't Touch Taro Until Management is GoneShlomo Greenberg • Thu, Sep 7, 2006
-
4 Low-Debt Healthcare Stocks Raking In ProfitsZetaKap • Fri, Sep 14, 2012
-
India Markets Wrap-Up: Auto Stocks Pull Markets LowerEquitymaster • Wed, May 30, 2012
-
India Markets Monday Wrap-Up: Sensex's Negative Trend ContinuesEquitymaster • Mon, Jan 31, 2011
-
India Market Wednesday Wrap-Up: Realty Strikes the Bull RunEquitymaster • Wed, Sep 22, 2010
-
India Markets Thursday Wrap-Up: Volatility Plagues the IndicesEquitymaster • Thu, Sep 16, 2010
-
Bullish Outlook for Generic Drugs Post-ElectionMike Havrilla • Mon, Nov 3, 2008
-
Overview and Analysis of the Global Generic Drug IndustryMike Havrilla • Mon, Oct 13, 2008
-
ClickSoftware Could Be Up For Sale SoonShlomi Cohen • Wed, Jul 11, 2007
There are no Transcripts on TARO.
-
Business Wire (Thu, 5:05PM)
-
Business Wire (May 16, 2013)
-
Business Wire (Apr 12, 2013)
-
Business Wire (Feb 8, 2013)
-
Business Wire (Feb 4, 2013)
-
Business Wire (Jan 25, 2013)
-
Business Wire (Nov 14, 2012)
-
Business Wire (Nov 8, 2012)
-
Business Wire (Nov 1, 2012)
-
Business Wire (Oct 23, 2012)
-
at CNBC.com (Aug 13, 2012)
-
Business Wire (Aug 12, 2012)
-
Business Wire (Aug 6, 2012)
-
Business Wire (Jul 30, 2012)
-
Business Wire (Jul 19, 2012)
-
Business Wire (Jun 28, 2012)
-
Business Wire (May 24, 2012)
-
Business Wire (May 18, 2012)
-
Business Wire (May 11, 2012)
TARO vs. ETF Alternatives
Company Description
Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, May 24, 11:01 AM Taro Pharmaceutical (TARO -7%) slides after earlier reporting Q1 earnings of $1.10 per share on net sales of $165.1M, an increase of 13.8%, from a year ago. Gross margin grew to 72.4% from 68.3%, offsetting an increase in Research and development expenses by 23.9% to $12.2M. Settlements and loss contingencies totalled $33.3M, dragging down operating income to $63.1M, or 38.2% of net sales, compared to $66.2 million, or 45.6% the year prior. 4 Comments [Healthcare, Earnings, On the Move]
- Friday, February 8, 9:12 AM Taro Pharmaceutical (TARO) and Sun Pharmaceutical mutually agree to terminate their merger agreement in which Sun - a 66% owner of Taro - would have paid $39.50 for the rest of the company (Taro closed at $50.55 last night). SA author Retail Investor has covered the saga here and here, and thinks Taro could be a triple. Shares +0.9% premarket. Comment! [Healthcare, On the Move, Quick Ideas]
- Monday, August 13, 2012, 8:58 AM Taro Pharmaceutical (TARO) agrees to be taken private by India’s Sun Pharmaceutical Industries for $39.50/share, a 60% increase from a prior offer of $24.50. Sun had already owned 66% of Taro prior to the buyout, which is worth $571M. Comment! [Healthcare, M&A]
-
- View all 1 replies
-
jaginger: Litigation expense took a bite out of qrtly earnings. R&D up significantly for the year vs last year.
-
Retail Investor
$AAPL $DELL $GOOG $TARO What Bill Ackman and Carl Icahn should be looking at -> http://bit.ly/18j6GKV - View all 0 replies
-
- View all 2 replies
-
Valuable Insights: What do you think it's worth? Do you think Sun Pharma comes in with another offer - and if so, will it be reasonable this time? Thanks - Val -
Chris DeMuth Jr.: Good question but a hard one to answer. It is probably worth at least $60 as a standalone but much more to Sun. Yes. They will be back.
-
Retail Investor
$DNDN $AMRN $TEVA $ARNA $CLSN $SPY $TARO Posts Strong Results -> http://bit.ly/THNRyQ - View all 0 replies
-
Retail Investor
$ESLT $CEL $TEVA $TARO - Shareholders discussion group to suggest proposals to maximize value -> http://bit.ly/RqPX2c - View all 0 replies
-
Retail Investor
$TARO $TEVA $PRGO $VRX $VRX TARO to announce results . Questions shareholders should ask on prelim proxy ->http://bit.ly/VUtMHc - View all 0 replies
LATEST REPLIES
-
- View all 2 replies
-
Valuable Insights: What do you think it's worth? Do you think Sun Pharma comes in with another offer - and if so, will it be reasonable this time? Thanks - Val -
Chris DeMuth Jr.: Good question but a hard one to answer. It is probably worth at least $60 as a standalone but much more to Sun. Yes. They will be back.



